Phaseline

Companies › Shanghai Xitaili Biomedicine Technology

Shanghai Xitaili Biomedicine Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XTL6001
triple-target GLP-1 receptor agonist
GLP1RPhase 1Weight Management in Adult Patients With Obesity or Overweight–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07205432XTL6001Phase 1Weight Management in Adult Patients With Obesity or OverweightMetabolic and endocrineApr 2026

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.